Connection

Maria Sormani to Multiple Sclerosis

Back to Details
This is a "connection" page, showing publications Maria Sormani has written about Multiple Sclerosis.
Maria Sormani
Connection Strength
3.856
Multiple Sclerosis
  1. Coronavirus disease 2019 in Latin American patients with multiple sclerosis. Mult Scler Relat Disord. 2021 Oct; 55:103173.
    View in: PubMed
    Score: 0.289
  2. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol. 2021 08; 8(8):1738-1744.
    View in: PubMed
    Score: 0.288
  3. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 04; 89(4):780-789.
    View in: PubMed
    Score: 0.280
  4. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol. 2020 06; 19(6):481-482.
    View in: PubMed
    Score: 0.265
  5. A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis. Mult Scler. 2020 08; 26(9):1064-1073.
    View in: PubMed
    Score: 0.249
  6. Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas. Ann Neurol. 2018 10; 84(4):621-625.
    View in: PubMed
    Score: 0.238
  7. Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials. Neurotherapeutics. 2017 Oct; 14(4):924-933.
    View in: PubMed
    Score: 0.222
  8. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology. 2017 May 30; 88(22):2115-2122.
    View in: PubMed
    Score: 0.215
  9. Why non-inferiority is more challenging than superiority? Mult Scler. 2017 05; 23(6):790-791.
    View in: PubMed
    Score: 0.214
  10. Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts. Mult Scler. 2017 Mar; 23(3):378-381.
    View in: PubMed
    Score: 0.213
  11. Indirect comparisons of treatment effects: Network meta-analyses. Mult Scler. 2017 Apr; 23(4):510-512.
    View in: PubMed
    Score: 0.213
  12. Approved drugs for multiple sclerosis: the challenge of choice. Lancet Neurol. 2017 04; 16(4):252-253.
    View in: PubMed
    Score: 0.212
  13. Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey. Neurol Sci. 2022 Feb; 43(2):1197-1205.
    View in: PubMed
    Score: 0.072
  14. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? Mult Scler Relat Disord. 2021 Jul; 52:102968.
    View in: PubMed
    Score: 0.071
  15. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler. 2021 12; 27(14):2126-2136.
    View in: PubMed
    Score: 0.069
  16. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. Mult Scler Relat Disord. 2020 Oct; 45:102359.
    View in: PubMed
    Score: 0.067
  17. Different MRI patterns in MS worsening after stopping fingolimod. Neurol Neuroimmunol Neuroinflamm. 2019 07; 6(4):e566.
    View in: PubMed
    Score: 0.062
  18. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018 10; 14(10):577-589.
    View in: PubMed
    Score: 0.059
  19. Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. Eur J Neurol. 2019 01; 26(1):162-167.
    View in: PubMed
    Score: 0.059
  20. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018 02; 24(2):96-120.
    View in: PubMed
    Score: 0.057
  21. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018 02; 25(2):215-237.
    View in: PubMed
    Score: 0.057
  22. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler. 2018 03; 24(3):245-255.
    View in: PubMed
    Score: 0.056
  23. Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. Neurology. 2017 Nov 28; 89(22):2222-2229.
    View in: PubMed
    Score: 0.056
  24. Maturational Trajectory of Processing Speed Performance in Pediatric Multiple Sclerosis. Dev Neuropsychol. 2017; 42(5):299-308.
    View in: PubMed
    Score: 0.055
  25. Three-Dimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease. J Neuroimaging. 2017 11; 27(6):613-619.
    View in: PubMed
    Score: 0.054
  26. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol. 2017 Apr 01; 74(4):459-469.
    View in: PubMed
    Score: 0.054
  27. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol. 2017 Feb; 13(2):105-118.
    View in: PubMed
    Score: 0.053
  28. Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis. Neuroimage Clin. 2014; 4:641-8.
    View in: PubMed
    Score: 0.044
  29. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017 03 21; 88(12):1144-1152.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.